Cargando…
YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage
Current standard of care for muscle-invasive urothelial cell carcinoma (UCC) is surgery along with perioperative platinum-based chemotherapy. UCC is sensitive to cisplatin-based regimens, but acquired resistance eventually occurs, and a subset of tumors is intrinsically resistant. Thus, there is an...
Autores principales: | Ciamporcero, Eric, Shen, He, Ramakrishnan, Swathi, Ku, Sheng Yu, Chintala, Sreenivasulu, Shen, Li, Adelaiye, Remi, Miles, Kiersten Marie, Ullio, Chiara, Pizzimenti, Stefania, Daga, Martina, Azabdaftari, Gissou, Attwood, Kris, Johnson, Candace, Zhang, Jianmin, Barrera, Giuseppina, Pili, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695331/ https://www.ncbi.nlm.nih.gov/pubmed/26119935 http://dx.doi.org/10.1038/onc.2015.219 |
Ejemplares similares
-
HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma
por: Ramakrishnan, Swathi, et al.
Publicado: (2016) -
Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts
por: Miles, Kiersten Marie, et al.
Publicado: (2014) -
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer
por: Kirk, Jason S., et al.
Publicado: (2014) -
Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer
por: Fontana, Luigi, et al.
Publicado: (2013) -
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial
por: Pili, Roberto, et al.
Publicado: (2017)